Rhythm Pharmaceuticals

Valuation Analysis

About the Company

Rhythm Pharmaceuticals en bref

Rhythm Pharmaceuticals (RYTM) is currently trading at 86,25 € with a market capitalization of 5,9 Md €. The 52-week range spans from 64,74 € to 106,20 €; the current price is 18.8% below the yearly high. Year-over-year revenue growth stands at +83.8%.

💰 Dividende

Rhythm Pharmaceuticals currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Avis des analystes

15 analystes évaluent Rhythm Pharmaceuticals (RYTM) au consensus : Achat Fort. L'objectif de cours moyen est de 120,62 €, soit un potentiel de +39.85% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 91,25 € à 134,70 €.

Rhythm Pharmaceuticals : la thèse d'investissement en détail

Rhythm Pharmaceuticals (RYTM) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

Le scénario haussier

Top-line momentum is unusually strong with revenue expanding 83.8% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind. With a gross margin near 89.41%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 39.85% upside from current levels — analyst sentiment is firmly constructive.

Le scénario baissier

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.88, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 14.07% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

À surveiller

• The analyst consensus price target implies 39.85% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Thèse d'investissement : forces et faiblesses

Aperçu technique

Price shows short-term weakness (below 50d MA) but is still in a longer-term uptrend (above 200d MA).

Profil de risque

The data points to above-average price swings, elevated short interest (14.07%).

Trading Data

Related Stocks in the Same Sector

Where can I buy Rhythm Pharmaceuticals?

Compare top-rated brokers — low fees, trusted providers, fully regulated.